The Food and Drug Administration is delaying by three months a decision on whether to approve a drug for preventing infection with HIV, the virus that causes AIDS.
An agency decision on the drug Truvada, made by Gilead Sciences, was expected by June 15. But the decision was pushed back to give the agency time to review a new Gilead plan to limit the risks to healthy people taking the drug, Cara Miller, a company spokeswoman, said Friday.
Last week, a group of 55 U.S. physicians sent a letter to the U.S. Food & Drug Administration (FDA), urging the agency not to approve the use of Gilead's HIV/AIDS treatment drug Truvada for use as an HIV prevention pill - also known... Read Post
(WASHINGTON) — Federal health regulators have delayed a decision on whether to approve the first pill shown to prevent HIV infection, the drug’s manufacturer says. Gilead Sciences disclosed Friday that the Food and Drug Administrati... Read Post